

Claudia Wellbrock

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4227594/claudia-wellbrock-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59 papers	5,236 citations	31 h-index	61 g-index
61 ext. papers	5,928 ext. citations	10.9 avg, IF	5.87 L-index

#	Paper	IF	Citations
59	Melanoma biology and new targeted therapy. <i>Nature</i> , 2007 , 445, 851-7	50.4	1018
58	The RAF proteins take centre stage. <i>Nature Reviews Molecular Cell Biology</i> , 2004 , 5, 875-85	48.7	922
57	V599EB-RAF is an oncogene in melanocytes. <i>Cancer Research</i> , 2004 , 64, 2338-42	10.1	298
56	Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. <i>PLoS ONE</i> , 2008 , 3, e2734	3.7	200
55	Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. <i>Molecular and Cellular Biology</i> , 2001 , 21, 2324-36	4.8	161
54	FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. <i>EMBO Journal</i> , 2006 , 25, 3078-88	13	150
53	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. <i>Cancer Cell</i> , 2016 , 29, 270-284	24.3	149
52	The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF. <i>Cancer Discovery</i> , 2014 , 4, 1214-1229	24.4	139
51	Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 390-406	4.5	138
50	Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. <i>Journal of Cell Biology</i> , 2005 , 170, 703-8	7.3	138
49	Heterogeneous tumor subpopulations cooperate to drive invasion. <i>Cell Reports</i> , 2014 , 8, 688-95	10.6	135
48	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. <i>Cell Reports</i> , 2017 , 20, 1818-1829	10.6	128
47	BRAF as therapeutic target in melanoma. <i>Biochemical Pharmacology</i> , 2010 , 80, 561-7	6	126
46	Phenotype plasticity as enabler of melanoma progression and therapy resistance. <i>Nature Reviews Cancer</i> , 2019 , 19, 377-391	31.3	125
45	The Brn-2 transcription factor links activated BRAF to melanoma proliferation. <i>Molecular and Cellular Biology</i> , 2004 , 24, 2923-31	4.8	102
44	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017 , 5, 390-390	3.2	78
43	Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 33-46	9.7	78

42	Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. <i>Journal of Biological Chemistry</i> , 2002 , 277, 6443-54	5.4	67
41	The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2016 , 4, 33	5.7	67
40	Overcoming resistance to BRAF inhibitors. <i>Annals of Translational Medicine</i> , 2017 , 5, 387	3.2	64
39	Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. <i>Cancer Research</i> , 2002 , 62, 4820-8	10.1	59
38	STAT5 contributes to interferon resistance of melanoma cells. <i>Current Biology</i> , 2005 , 15, 1629-39	6.3	52
37	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. <i>Journal of Experimental Medicine</i> , 2017 , 214, 1691-1710	16.6	51
36	Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing. <i>Oncogene</i> , 2018 , 37, 3166-3182	9.2	51
35	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1011-1029	12	49
34	Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase. <i>Oncogene</i> , 2002 , 21, 1668-78	9.2	44
33	Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain. <i>Journal of Biological Chemistry</i> , 2001 , 276, 3333-40	5.4	38
32	Identification of a second egfr gene in Xiphophorus uncovers an expansion of the epidermal growth factor receptor family in fish. <i>Molecular Biology and Evolution</i> , 2004 , 21, 266-75	8.3	35
31	Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth. <i>Oncotarget</i> , 2017 , 8, 32946-32959	3.3	32
30	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. <i>Cancer Discovery</i> , 2017 , 7, 832-851	24.4	31
29	Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma. <i>Oncogene</i> , 1998 , 16, 3047-56	9.2	31
28	Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance. <i>Clinical Cancer Research</i> , 2016 , 22, 5966-5970	12.9	30
27	Multiple binding sites in the growth factor receptor Xmrk mediate binding to p59fyn, GRB2 and Shc. <i>FEBS Journal</i> , 1999 , 260, 275-83		30
26	Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells. <i>Journal of Cell Science</i> , 2014 , 127, 1346-56	5.3	29
25	Activation of the Xmrk proto-oncogene of Xiphophorus by overexpression and mutational alterations. <i>Oncogene</i> , 1998 , 16, 1681-90	9.2	29

24	Differentiation of THP1 Cells into Macrophages for Transwell Co-culture Assay with Melanoma Cells. <i>Bio-protocol</i> , 2015 , 5,	0.9	29
23	Targeting invasive properties of melanoma cells. <i>FEBS Journal</i> , 2017 , 284, 2148-2162	5.7	26
22	MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1236-46	6.1	26
21	STAT5 contributes to antiapoptosis in melanoma. <i>Melanoma Research</i> , 2008 , 18, 378-85	3.3	26
20	The oncogenic epidermal growth factor receptor variant Xiphophorus melanoma receptor kinase induces motility in melanocytes by modulation of focal adhesions. <i>Cancer Research</i> , 2006 , 66, 3145-52	10.1	26
19	Activation of phosphatidylinositol 3-kinase by a complex of p59fyn and the receptor tyrosine kinase Xmrk is involved in malignant transformation of pigment cells. <i>FEBS Journal</i> , 2000 , 267, 3513-22		26
18	Melanoma development and pigment cell transformation in xiphophorus. <i>Microscopy Research and Technique</i> , 2002 , 58, 456-63	2.8	25
17	Receptor tyrosine kinase Xmrk mediates proliferation in Xiphophorus melanoma cells. <i>International Journal of Cancer</i> , 1998 , 76, 437-42	7.5	23
16	Activating mutations in the extracellular domain of the melanoma inducing receptor Xmrk are tumorigenic in vivo. <i>International Journal of Cancer</i> , 2005 , 117, 723-9	7.5	21
15	PI3-kinase is involved in mitogenic signaling by the oncogenic receptor tyrosine kinase Xiphophorus melanoma receptor kinase in fish melanoma. <i>Experimental Cell Research</i> , 1999 , 251, 340-9	4.2	21
14	A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF /AXL melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019 , 32, 280-291	4.5	20
13	MAPK pathway inhibition in melanoma: resistance three ways. <i>Biochemical Society Transactions</i> , 2014 , 42, 727-32	5.1	18
12	MITF-M plays an essential role in transcriptional activation and signal transduction in Xiphophorus melanoma. <i>Gene</i> , 2003 , 320, 117-26	3.8	18
11	Signal transduction by the oncogenic receptor tyrosine kinase Xmrk in melanoma formation of Xiphophorus. <i>Pigment Cell & Melanoma Research</i> , 1997 , 10, 34-40		17
10	Cooperative behaviour and phenotype plasticity evolve during melanoma progression. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 695-708	4.5	9
9	Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies. <i>EMBO Molecular Medicine</i> , 2015 , 7, 1087-9	12	8
8	The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. <i>Immunology</i> , 2010 , 129, 610-9	7.8	8
7	Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 74-85	4.5	4

- 6 Melanoma and the Microenvironment--Age Matters. *New England Journal of Medicine*, **2016**, 375, 696-8 59.2 2
- 5 Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. *Molecular Cancer*, **2014**, 13, 154 42.1 2
- 4 DGAT1 is a lipid metabolism oncoprotein that enables cancer cells to accumulate fatty acid while avoiding lipotoxicity 1
- 3 Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma. *Cancers*, **2021**, 13, 6.6 1
- 2 A two-step selection approach for the identification of ligand-binding determinants in cytokine receptors. *Analytical Biochemistry*, **1999**, 268, 179-86 3.1
- 1 Melanoma Development and Pigment Cell Transformation **2006**, 247-263